# Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

> **NCT05428215** · PHASE4 · TERMINATED · sponsor: **MaineHealth** · enrollment: 2 (actual)

## Conditions studied

- Gender Dysphoria

## Interventions

- **DRUG:** 17beta Estradiol

## Key facts

- **NCT ID:** NCT05428215
- **Lead sponsor:** MaineHealth
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Inability to adequately recruit participants, need for additional study participants based on preliminary data collection
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428215, "Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05428215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*